HIND Vyome Holdings, Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1427570 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-55.6%
TTM net income YoY59.8%
TTM EPS YoY100.2%
Revenue 3-yr CAGR-75.0%
Net income 3-yr CAGR—
Margins
Gross margin50.4%
Operating margin-2,853.6%
Net margin-2,455.6%
FCF margin—
EBITDA margin-2,846.7%
Returns
ROE-95.7%
ROA-48.0%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets24.0%
Debt / equity0.00x
Current ratio3.68x
Interest coverage-229.34x
Cash quality & payout
Operating cash flow / net income1.18x
Accruals ratio8.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $57,998 | $26,955 | $31,591 | $36,551 | $34,627 | $49,954 | $198,581 | $61,428 |
| Cost of revenue | $31,196 | $15,297 | $14,946 | $14,485 | $16,577 | $25,719 | $44,162 | -$1,333 |
| Gross profit | $26,802 | $11,658 | $16,645 | $22,066 | $18,050 | $24,235 | $154,419 | $62,761 |
| R&D expense | $409,831 | $506,723 | $666,405 | $378,252 | $39,677 | $80,061 | $90,268 | $67,527 |
| SG&A expense | $635,410 | $364,891 | $477,575 | $996,200 | $844,344 | $265,395 | $259,626 | $247,376 |
| Operating income | -$1.02M | -$862,566 | -$1.13M | -$1.36M | -$8.57M | -$324,189 | -$198,998 | -$256,006 |
| Interest expense | $2,935 | $3,325 | $2,845 | $9,944 | $25,604 | $56,139 | $54,954 | $52,775 |
| Pretax income | — | — | — | — | — | -$2.62M | $1.48M | -$1.76M |
| Income tax | — | — | — | — | — | $8,000 | $7,000 | $5,000 |
| Net income | -$885,408 | -$685,556 | -$962,910 | -$1.23M | -$8.43M | -$308,760 | -$293,974 | -$306,557 |
| EBITDA | -$1.02M | -$859,956 | -$1.13M | -$1.35M | -$8.57M | -$321,221 | -$195,475 | -$252,142 |
| EPS (basic) | -0.13 | -0.10 | -0.15 | — | -3.06 | -799.90 | -761.59 | — |
| EPS (diluted) | -0.13 | -0.10 | -0.15 | — | -3.06 | -799.90 | -761.59 | — |
| Weighted avg. shares (diluted) | — | — | 6.69M | — | 2.76M | 1.17M | 386 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $6.96M | $7.89M | $8.80M | $4.98M | $5.71M | $383,386 | $58,370 | $101,904 |
| Receivables | $9,096 | $2,181 | $309 | $325 | $23,001 | $1.40M | $700,000 | $2,294 |
| Inventory | — | — | — | — | — | $2.55M | $2.53M | $2.46M |
| Current assets | $7.60M | $8.15M | $9.16M | $5.44M | $6.04M | $8.86M | $6.29M | $302,046 |
| PP&E, net | $41,254 | $42,416 | $44,429 | $46,393 | $50,168 | $30,000 | $34,000 | $59,179 |
| Intangibles | $314,191 | $314,191 | $314,191 | $314,191 | $314,191 | — | — | $314,191 |
| Total assets | $8.61M | $9.18M | $10.19M | $6.50M | $7.05M | $9.03M | $1.44M | $1.38M |
| Current liabilities | $2.07M | $1.86M | $2.14M | $2.74M | $3.12M | $3.20M | $4.12M | $5.74M |
| Short-term debt | — | — | — | — | — | — | — | $811,000 |
| Total liabilities | $2.07M | $1.86M | $2.14M | $2.74M | $3.13M | $3.20M | $5.25M | $5.77M |
| Shareholders' equity | $5.33M | $6.05M | $6.74M | $2.44M | $2.53M | $5.83M | $1.23M | -$4.39M |
| Shares outstanding | 7.02M | 7.02M | 7.02M | 5.92M | — | 2.62M | 133,081 | 0 |
| Cash flow statement | ||||||||
| Operating cash flow | -$627,577 | -$903,712 | -$1.44M | -$1.48M | -$1.72M | -$306,251 | -$203,533 | -$2,968 |
| Investing cash flow | — | — | — | — | — | — | — | $1,466 |
| Financing cash flow | -$289,075 | -$3,000 | $5.29M | $764,020 | $7.06M | $631,253 | $160,000 | $53,466 |
| Depreciation & amortization | $2,702 | $2,610 | $2,605 | $2,688 | $2,806 | $2,968 | $3,523 | $3,864 |
| Stock-based compensation | $175,804 | $11,051 | $5,696 | $3,019 | $574,109 | $12,000 | $0 | $15,000 |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.